The Latest

Targeted Therapy for Children with ALK-Driven Neuroblastoma

Lorlatinib may prove effective for the treatment of neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.

TWIPO #66 – Interview with Dr. Rani George

Host Dr. Ryan Roberts, from Nationwide Children`s Hospital, interviews Dr. Rani George, Dana Farber/Boston Children`s Center, about progress being made in pediatric cancer research

Lace Up for Kids

This September, Solving Kids` Cancer is raising awareness for childhood cancer awareness month by distributing free gold shoelaces as part of their #LaceUpforKids campaign.

TWiPO #63 – Interview with Dr. Javier Blanco

Twipo hosts and co-hosts interview Dr. Javier Blanco, SUNY Buffalo, about the toxic, long term effects that various chemotherapy drugs can have on heart tissue. 

TWiPO #64 – Interview with Dr. Lars Wagner

Dr. Timothy Cripe, along with cohosts Dr. Keri Streby, Dr. Nilay Shah and Dr. Ryan Roberts, interview special guest Dr. Lars Wagner, Chief of Pediatric Hematology/Oncology, University of Kentucky.

TWIPO #61 – Interview with Dr. Matthew Breen

TWIPO hosts and cohosts interview Dr. Matthew Breen, NC State Veterinary Medicine, on his research with various dog genomes, and whether or not dogs can “teach us new tricks” when it comes to cancer treatment.

TWiPO #62 – Interview with Dr. Uri Tabori

TWiPO hosts and cohosts interview Dr. Uri Tabori, Hospital for Sick Kids, Toronto, about the challenges that are unique to pediatric brain tumors and how preventative treatment and early diagnosis can be largely beneficial.  

Advocacy in Action

Solving Kids` Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC`s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma. 

Precision Medicine Advances for Children With Neuroblastoma

November 17, 2016

Next Generation Personalized Neuroblastoma Therapy gives hope to children with relapse or refractory disease.